Physician profile
Gary William Thompson
NPI 1609838937
$7,643.06
in general payments reported to CMS, 2019-2025
28 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $453 · 2021: $1,159 · 2022: $1,833 · 2023: $1,524 · 2024: $1,064 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.83 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.81 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $1,648.28 | 2021-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,157.75 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $543.05 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $409.32 | 2022-2025 | Ibsrela |
| Celgene Corporation | $384.97 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $349.90 | 2019-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $228.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.99 | 2019-2025 | Eohilia |
| Ferring Pharmaceuticals INC. | $179.71 | 2019-2023 | Clenpiq |
| Gilead Sciences, INC. | $134.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $122.23 | 2022-2025 | Dupixent |
| Echosens North America, INC. | $117.00 | 2023 | Fibroscan |
| Braintree Laboratories, INC. | $74.60 | 2019-2023 | Sutab |
| E.R. Squibb & Sons, L.L.C. | $66.99 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $49.16 | 2023-2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.19 | 2020-2021 | |
| Madrigal Pharmaceuticals | $26.02 | 2025 | Rezdiffra |
| Pfizer INC. | $24.63 | 2025 | |
| Ucb, INC. | $20.63 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.21 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $17.01 | 2025 | Zenpep |
| Allergan, INC. | $15.97 | 2019 | |
| W. L. Gore & Associates, INC. | $15.01 | 2023 | Gore Cardioform Septal Occluder |
| Evoke Pharma, INC. | $14.02 | 2022 | |
| Genzyme Corporation | $13.71 | 2022 | |
| Kerecis Limited | $11.82 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Olympus America INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.